Page 17 - நோவர்த்திச் நிறுவனங்கள் க்கு உயிர் மருத்துவ ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நோவர்த்திச் நிறுவனங்கள் க்கு உயிர் மருத்துவ ஆராய்ச்சி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நோவர்த்திச் நிறுவனங்கள் க்கு உயிர் மருத்துவ ஆராய்ச்சி Today - Breaking & Trending Today

Folate Receptor-targeting Drug Seen to Lessen Inflammation in MS Rat Study

4.4
(9)
A novel medication targeting the protein folate receptor-beta (FR-beta) decreased inflammation and brain damage in a rat model of multiple sclerosis (MS).
The findings were published in the
MS is caused by the immune system attacking the nervous system, and one type of immune cell involved in this attack is the macrophage. In animal models of MS, inflammation-driving macrophages express the protein FR-beta, suggesting that this protein may be a viable therapeutic target.
In the new study, researchers from the University of Turku, Purdue University, and Endocyte (now part of Novartis Institutes for BioMedical Research) tested an investigational FR-beta-targeting medication called EC2319 in a rat model of MS. ....

United States , Yingjuan June Lu , Anne Roivainen , Purdue University , Novartis Institutes For Biomedical Research , Leiden University Medical Center , University Of Pittsburgh , Society Of America , University Of Turku , Novartis Institutes , Biomedical Research , Molecular Pathology , Medical Microbiology , Infectious Diseases , Applied Biology , Instituto De Medicina Molecular , ஒன்றுபட்டது மாநிலங்களில் , பர்‌ட்யூ பல்கலைக்கழகம் , நோவர்த்திச் நிறுவனங்கள் க்கு உயிர் மருத்துவ ஆராய்ச்சி , பல்கலைக்கழகம் ஆஃப் பிட்ஸ்பர்க் , சமூகம் ஆஃப் அமெரிக்கா , பல்கலைக்கழகம் ஆஃப் டர்கு , நோவர்த்திச் நிறுவனங்கள் , உயிர் மருத்துவ ஆராய்ச்சி , மூலக்கூறு நோயியல் , மருத்துவ நுண்ணுயிரியல் ,

The myth-buster - Chinadaily.com.cn

China Daily Global /
2021-02 /
01 /
Page015
The myth-buster
Li Zhizhong is on a mission to provide accurate information about cancer, Wang Qian reports.
Every minute last year, on average, nine people in China were diagnosed with cancer, while six others died from it, according to the latest data from the International Agency for Research on Cancer of the World Health Organization, which was released in December.
It is estimated that by the age of 75, one in four people in China will develop cancer in one form or another, which means that it can affect anyone. But for Li Zhizhong, while such figures may paint a bleak picture, a cancer diagnosis doesn t necessarily mean a death sentence. ....

United States , Wang Qian , Li Zhizhong , Wei Zexi , Zeng Yixin , Novartis Institutes For Biomedical Research , National Health Commission , Shiyu Children Foundation , Xidian University In Shaanxi , China Daily , Tsinghua University , Duke University , International Agency , World Health Organization , Truth About Cancer , Xidian University , Novartis Institutes , Biomedical Research , Oncology Drug Discovery , Cancer Insights , ஒன்றுபட்டது மாநிலங்களில் , நோவர்த்திச் நிறுவனங்கள் க்கு உயிர் மருத்துவ ஆராய்ச்சி , தேசிய ஆரோக்கியம் தரகு , சீனா தினசரி , டியூக் பல்கலைக்கழகம் , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் ,

Novartis and GSK announce collaboration to support scientifi

ng
Therapeutics (GRADIENT), with a combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years, calls on African researchers to submit robust research proposals on the relevance of African genetic diversity to the treatment of malaria and tuberculosis (TB).
1
Lutz Hegemann, M.D., Chief Operating Officer for Global Health at Novartis said: “Novartis has a long-standing commitment to improving and extending the lives of patients around the world. Our efforts include seeking innovative ways to improve the standard of care where possible. This is why we are excited by this important collaboration on scientific research on genetic diversity in Africa. It has the potential to improve the efficacy and tolerability of current and future medicines, starting with two of the most deadly diseases, malaria and tuberculosis. In alignment with our ongoing efforts to strengthen scientific capabilities in lower-resource settings, this project also provides op ....

United States , Isabella Zinck , Eric Althoff , Thomas Hungerbuehler , Kara Cournoyer , Glenda Gray , Samir Shah , Lutz Hegemann , Sloan Simpson , Katerina Kontzalis , Antonio Ligi , Pauline Williams , Novartis Global Health Corporate Responsibility , Global Health Pharma , Novartis Institutes For Biomedical Research , Novartis Institutes For Biomedical Research On African , Steering Committee , Global Health At Novartis , Global Health Cr Communications , Novartis Us External Communications , Novartis External Communications , Exchange Commission , Africa Medical Research Council , African Medical Research Council , Africa Genomic Research Approach For Diversity , Project Africa Genomic Research Approach ,

GSK and Novartis announce collaboration to support scientific research into genetic diversity in Africa

ng
Therapeutics (GRADIENT), with a combined funding commitment of GBP 2.8m (USD 3.6 million) over five years, calls on African researchers to submit robust research proposals on the relevance of African genetic diversity to the treatment of malaria and tuberculosis.
1
Pauline Williams, Senior Vice President Global Health Pharma at GSK said: “At GSK, human genetics is a core pillar of our R&D strategy. Genetic diversity is greater in Africa than in any other continental population resulting in some African patients having varying response to treatments. We are excited to launch Project Africa GRADIENT which aims to catalyse the best science in the continent to optimize treatment responses for malaria and tuberculosis, two infectious diseases that disproportionately affect African populations.” ....

United Kingdom , Nairobi Area , United States , City Of , Simon Moore , Thomas Hungerbuehler , Jeff Mclaughlin , Simon Steel , Danielle Smith , Glenda Gray , Samir Shah , Lutz Hegemann , Ben Agina , Antonio Ligi , Sarah Elton Farr , Isabella Zinck , Evan Berland , Eric Althoff , Kara Cournoyer , Omongiade Ehighebolo , James Dodwell , Cory Twining , Sloan Simpson , Katerina Kontzalis , Pauline Williams , Novartis Global Health Corporate Responsibility ,

Medication shows promise for weight loss in patients with obesity, diabetes

E-Mail
SILVER SPRING, Md. A new study confirms that treatment with Bimagrumab, an antibody that blocks activin type II receptors and stimulates skeletal muscle growth, is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes.
These exciting results suggest that there may be a novel mechanism for achieving weight loss with a profound loss of body fat and an increase in lean mass, along with other metabolic benefits, said Steve Heymsfield, MD, FTOS, past president of The Obesity Society and corresponding author of the study. Heymsfield is professor and director of the Metabolism and Body Composition Laboratory at the Pennington Biomedical Research Center in Baton Rouge, La. ....

United States , United Kingdom , Abram Miller , Didier Laurent , Therese Swan , Ronenn Roubenoff , Laura Coleman , Las Vegas , Thomas Wade , Robert Perry , Daniel Rooks , Steve Heymsfield , Jens Praestgaard , Bret Goodpaster , Olivier Petricoul , Novartis Institutes For Biomedical Research , Qps Miami Research Associates In , Body Composition Laboratory , Obesity Society , Pennington Biomedical Research Center , Novartis Institutes Of Biomedical Research In Basel , Panax Clinical Research Of Miami , Advent Health Research Institute In Orlando , Baton Rouge , Pharmacological Anti Obesity , Translational Medicine ,